Loading...

MedXY AI/MedXY News/Tag: heart failure

MedXY News

EnglishTag

heart failure

147 all articles · 20 / page

Ask MedXY AI

clinical trial type 2 diabetes heart failure immunotherapy obesity atrial fibrillation Cardiology oncology cardiovascular risk biomarkers clinical trials public health Hypertension critical care breast cancer artificial intelligence Alzheimer's disease diabetes nutrition chronic kidney disease cardiovascular disease Pediatrics

Latest news

Tag

PANDA II Trial Confirms Influenza Vaccination as Essential Intervention for Acute Heart Failure Patients

PANDA II Trial Confirms Influenza Vaccination as Essential Intervention for Acute Heart Failure Patients

The PANDA II study demonstrates that influenza vaccination significantly reduces mortality and rehospitalization in acute heart failure patients, supporting its inclusion as a standard component of heart failure management worldwide.

Section: CardiologyOct 7, 2025

Myocardial T1 Mapping and Extracellular Volume: Emerging Prognostic Tools in Heart Failure and Non-Ischaemic Dilated Cardiomyopathy

Myocardial T1 Mapping and Extracellular Volume: Emerging Prognostic Tools in Heart Failure and Non-Ischaemic Dilated Cardiomyopathy

Cardiac MRI T1 mapping and extracellular volume fraction (ECV) provide noninvasive markers of myocardial fibrosis, showing consistent prognostic value across heart failure subtypes and non-ischaemic dilated cardiomyopathy for adverse cardio

Section: CardiologyOct 7, 2025

Low-Dose Digoxin Enhances Cardiac Function in Heart Failure with Preserved EF and Atrial Fibrillation: Insights from the RATE-AF Trial

Low-Dose Digoxin Enhances Cardiac Function in Heart Failure with Preserved EF and Atrial Fibrillation: Insights from the RATE-AF Trial

The RATE-AF trial demonstrates that low-dose digoxin significantly improves systolic function and symptoms in patients with heart failure, preserved ejection fraction, and permanent atrial fibrillation compared to beta-blockers, with fewer

Section: CardiologyOct 7, 2025

Decoding Heart Failure Risk: Integrated Systolic and Diastolic Function Trajectories and Proteomic Insights

Decoding Heart Failure Risk: Integrated Systolic and Diastolic Function Trajectories and Proteomic Insights

Bayesian modelling of combined systolic and diastolic function trajectories in older adults reveals distinct patterns predicting heart failure subtypes and identifies potential proteomic targets for therapy.

Section: CardiologyOct 7, 2025

Decoding Cardiac Trajectories: Linking Systolic-Diastolic Function Patterns to Heart Failure Risk and Proteomics

Decoding Cardiac Trajectories: Linking Systolic-Diastolic Function Patterns to Heart Failure Risk and Proteomics

This study integrates longitudinal systolic and diastolic cardiac function measures using Bayesian modeling to identify trajectories associated with distinct heart failure subtypes and proteomic signatures, enhancing risk prediction and the

Section: CardiologyOct 7, 2025

Harnessing Mobile Technology for Early Heart Failure Detection: Insights from the ECHOS3 Registry in Primary Care

Harnessing Mobile Technology for Early Heart Failure Detection: Insights from the ECHOS3 Registry in Primary Care

Mobile app-assisted screening in primary care settings identified new heart failure cases in one-third of at-risk patients, especially those with preserved ejection fraction, highlighting a promising route for early diagnosis.

Section: AIOct 7, 2025

Personalized Accelerated Physiologic Pacing Shows Promise in HFpEF: Insights from the myPACE Trial Extension

Personalized Accelerated Physiologic Pacing Shows Promise in HFpEF: Insights from the myPACE Trial Extension

Personalized increased pacing rates in patients with HFpEF and physiologic pacemakers may reduce adverse events and improve event-free survival, per a 4-year observational extension of the myPACE randomized trial.

Section: CardiologyOct 6, 2025

Five Key Lessons From the DIGIT-HF Trial: Revisiting Digitoxin in HFrEF Management

Five Key Lessons From the DIGIT-HF Trial: Revisiting Digitoxin in HFrEF Management

The DIGIT-HF trial sheds new light on digitoxin’s role in heart failure with reduced ejection fraction, revealing safety, efficacy, and clinical implications despite contemporary therapies.

Section: CardiologyOct 6, 2025

Digitoxin Revisited: A Renewed Therapeutic Avenue for Advanced Heart Failure Patients

Digitoxin Revisited: A Renewed Therapeutic Avenue for Advanced Heart Failure Patients

The DIGIT-HF trial reveals that adding low-dose digitoxin to standard heart failure treatment reduces hospitalization and all-cause mortality in symptomatic HFrEF patients, highlighting a potential resurgence for this historic cardiac glyco

Section: CardiologyOct 6, 2025

Heart Failure Isn’t Scary — Ignoring Early Signs Is: Prevention for 6 High-Risk Groups

Heart Failure Isn’t Scary — Ignoring Early Signs Is: Prevention for 6 High-Risk Groups

Heart failure is a serious but manageable condition. Recognizing early symptoms and understanding risk factors can save lives. Here’s a comprehensive guide on prevention, diagnosis, and management for both the public and health professional

Section: CardiologyOct 6, 2025

Diuretic-Sparing Potential of Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: Insights from FINEARTS-HF

Diuretic-Sparing Potential of Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: Insights from FINEARTS-HF

Finerenone consistently reduces heart failure events and allows reduction of loop diuretic dosages without impacting new loop diuretic initiation, demonstrating a diuretic-sparing effect in HFmrEF/HFpEF patients.

Section: CardiologyOct 5, 2025

Unraveling Molecular Links Between Chronic Kidney Disease and Heart Failure via the Plasma Proteome

Unraveling Molecular Links Between Chronic Kidney Disease and Heart Failure via the Plasma Proteome

A comprehensive proteomic analysis from the ARIC study identifies plasma proteins linking kidney dysfunction to incident heart failure, highlighting potential biomarkers and therapeutic targets for HF prevention in CKD patients.

Section: CardiologyOct 4, 2025

Left Atrial Volumetric/Mechanical Coupling Index in Heart Failure With Preserved Ejection Fraction

Left Atrial Volumetric/Mechanical Coupling Index in Heart Failure With Preserved Ejection Fraction

This study explores the Left Atrial Coupling Index as a key predictor in heart failure patients with preserved ejection fraction.

Section: CardiologyOct 4, 2025

Risks and Realities of Withdrawing Heart Failure Medications After Ejection Fraction Improvement

Risks and Realities of Withdrawing Heart Failure Medications After Ejection Fraction Improvement

Withdrawal of renin-angiotensin inhibitors and mineralocorticoid receptor antagonists in patients with heart failure and improved ejection fraction significantly increases 1-year cardiovascular mortality and hospitalization risks; beta-bloc

Section: CardiologyOct 3, 2025

Optimizing Blood Transfusion Strategies in Acute Myocardial Infarction with Anemia and Heart Failure: Insights from the MINT Trial

Optimizing Blood Transfusion Strategies in Acute Myocardial Infarction with Anemia and Heart Failure: Insights from the MINT Trial

The MINT trial reveals that liberal transfusion strategies in MI patients with anemia, including those with heart failure, reduce adverse outcomes compared to restrictive transfusion, supporting a tailored approach to transfusion management

Section: AnesthesiologyOct 3, 2025

Decade-Long Insights into Deferred Versus Immediate Stenting in STEMI Patients: DANAMI-3-DEFER Trial Findings

Decade-Long Insights into Deferred Versus Immediate Stenting in STEMI Patients: DANAMI-3-DEFER Trial Findings

The 10-year DANAMI-3-DEFER study compared deferred stenting to immediate stenting in STEMI, showing no mortality benefit but reduced heart failure hospitalizations with deferred stenting.

Section: CardiologyOct 3, 2025

Advancements in Transcatheter Edge-to-Edge Repair for Severe Tricuspid Regurgitation: Insights from the TRILUMINATE Pivotal Trial

Advancements in Transcatheter Edge-to-Edge Repair for Severe Tricuspid Regurgitation: Insights from the TRILUMINATE Pivotal Trial

Transcatheter edge-to-edge repair (TEER) offers a safe, effective option to reduce tricuspid regurgitation severity, improve quality of life, and lower heart failure hospitalizations up to two years, including in patients with cardiac impla

Section: CardiologyOct 3, 2025

Pregnancies Following Peri-Partum Cardiomyopathy: Insights from the ESC EuroObservational Research Programme

Pregnancies Following Peri-Partum Cardiomyopathy: Insights from the ESC EuroObservational Research Programme

This study analyses maternal and neonatal outcomes in subsequent pregnancies after peri-partum cardiomyopathy (PPCM), revealing lower than expected maternal risks and suggesting potential reclassification of pregnancy risk categories based

Section: CardiologyOct 3, 2025

Leveraging AI-Driven Care to Significantly Reduce Heart Failure Readmissions: The Linea Model

Leveraging AI-Driven Care to Significantly Reduce Heart Failure Readmissions: The Linea Model

Linea integrates generative AI and high-touch virtual nursing to proactively manage heart failure patients, achieving a 50% reduction in hospital readmissions within 90 days, substantially lowering costs and improving patient outcomes.

Section: AIOct 3, 2025

Anaemia as a Predictor of Iron Dysregulation and Modulator of Empagliflozin Response in Heart Failure with Reduced Ejection Fraction: Insights from the EMPATROPISM-FE Trial

Anaemia as a Predictor of Iron Dysregulation and Modulator of Empagliflozin Response in Heart Failure with Reduced Ejection Fraction: Insights from the EMPATROPISM-FE Trial

In patients with heart failure and reduced ejection fraction, anaemia predicts iron homeostasis disruption and influences response to empagliflozin, which increases myocardial iron and improves cardiac function and exercise capacity.

Section: CardiologyOct 3, 2025

Prev 1 5 6 7 8 Next